Roivant Sciences Ltd.

NasdaqGS:ROIV

Sector

🏥 Health Care

Industries

💊 Pharmaceuticals

🧬 Biotechnology

🔬 Clinical Trials

💄 Cosmetics

Location

United Kingdom

Market Cap

USD 7.78 B

Share Price

USD 11.45

Avg Daily Volume

6,663,046

Change (1 day)

0.09%

Change (1 year)

6.02%

Change (YTD)

-3.21%

Roivant Sciences Ltd. EBITDA for the Trailing 12 Months (TTM) ending March 31, 2025: USD -689.14 M

Roivant Sciences Ltd. EBITDA is USD -689.14 M for the Trailing 12 Months (TTM) ending March 31, 2025, a -115.05% change year over year. EBITDA means earnings before interest, taxes, depreciation, and amortization, which measures a company's operating performance by excluding non-operating expenses.

Roivant Sciences Ltd. EBITDA for the Trailing 12 Months (TTM) ending June 30, 2024 was USD 4.58 B.
Roivant Sciences Ltd. EBITDA for the Trailing 12 Months (TTM) ending June 30, 2021 was USD -480.63 M.

Quarterly
Annual
TTM

From:

To:

Zoom:

Key data

Date	EBITDA	Net Income	EPS (Diluted)	Shares (Diluted, Weighted)

NasdaqGS: ROIV

Roivant Sciences Ltd.

CEO	Mr. Matthew Gline
IPO Date	Dec. 8, 2020
Location	United Kingdom
Headquarters	11-12 St. James's Square
Employees	908
Sector	🏥 Health Care
Industries Pharmaceuticals 🧬 Biotechnology 🔬 Clinical Trials 💄 Cosmetics

Description

Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia. The company was founded in 2014 and is based in London, the United Kingdom.